Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21843417 | 0.86 | USP2 (0.43) | USP2SMN1; SMN2RECQLDDB1CRBN | |
| SCHEMBL2428542 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2GPR119RECQLDDB1 | |
| SCHEMBL319772 | 0.85 | USP2 (0.47) | USP2SMN1; SMN2GPR119RECQLDDB1 | |
| SCHEMBL18053621 | 0.82 | USP2 (0.59) | USP2SMN1; SMN2GPR119RECQLALOX15 | |
| SCHEMBL17760306 | 0.82 | USP2 (0.46) | USP2SMN1; SMN2GPR119RECQLDDB1 | |
| SCHEMBL359832 | 0.80 | USP2 (0.45) | USP2SMN1; SMN2GPR119RECQLDDB1 | |
| Hydrochloric Acid SCHEMBL30540029 | 0.79 | GPR119 (0.41) | USP2SMN1; SMN2GPR119RECQLDDB1 | |
| SCHEMBL4278413 | 0.79 | USP2 (0.54) | USP2SMN1; SMN2GPR119RECQLHRH3 | |
| SCHEMBL20975414 | 0.78 | GPR119 (0.41) | USP2SMN1; SMN2GPR119 | |
| SCHEMBL22911795 | 0.78 | USP2 (0.44) | USP2SMN1; SMN2GPR119RECQLDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12012393-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2024-06-18 | — | — | US | disclosed |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | HELIOEAST PHARMACEUTICAL CO., LTD. (CN) | 2023-05-16 | — | — | US | disclosed |
| WO-2022267495-A1 | NITROGEN-CONTAINING OXA-SPIROCYCLIC COMPOUND AND USE THEREOF | 南昌弘益药业有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | Inthera Bioscience AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-20220119401-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | HELIOEAST SCIENCE & TECHNOLOGY CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| US-11306068-B2 | Oxopiperazine derivatives | Inthera Bioscience AG (CH) | 2022-04-19 | — | — | US | disclosed |
| EP-3851440-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | Medshine Discovery Inc. (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-10626125-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3212618-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10329308-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180208607-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9850245-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170275283-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2017-09-28 | — | — | US | disclosed |
| EP-3212618-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016069426-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | disclosed |
| EP-2590985-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004400-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213057-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | USP2 3518/4885SMN1; SMN2 1963/4885GPR119 610/4885 |
| US-11306068-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | USP2 3518/4885SMN1; SMN2 1963/4885GPR119 610/4885 |
| US-20220119401-A1 | CYCLOPROPYLAMINE COMPOUND AS LSD1 INHIBITOR AND USE THEREOF | KDM1B, KDM1A, KDM7A | USP2 516/4885SMN1; SMN2 1937/4885GPR119 485/4885 |
| US-20250115571-A1 | OXOPIPERAZINE DERIVATIVES | CYP3A5, AQP1, AVPR2 | USP2 3518/4885SMN1; SMN2 1963/4885GPR119 610/4885 |
| US-10626125-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | USP2 4400/4885SMN1; SMN2 1148/4885GPR119 748/4885 |
| US-20180208607-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | USP2 4400/4885SMN1; SMN2 1148/4885GPR119 748/4885 |
| US-10329308-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | USP2 4400/4885SMN1; SMN2 1148/4885GPR119 748/4885 |
| US-20170275283-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | USP2 4805/4885SMN1; SMN2 1659/4885GPR119 1088/4885 |
| US-11649245-B2 | Cyclopropylamine compound as LSD1 inhibitor and use thereof | KDM1B, KDM1A, KDM7A | USP2 516/4885SMN1; SMN2 1937/4885GPR119 485/4885 |
| US-12012393-B2 | Oxopiperazine derivatives | CYP3A5, AQP1, AVPR2 | USP2 3518/4885SMN1; SMN2 1963/4885GPR119 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.